Pieris Pharmaceuticals (PIRS) Stock Rating Lowered by ValuEngine

Pieris Pharmaceuticals (NASDAQ:PIRS) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

Separately, HC Wainwright set a $9.00 price target on Pieris Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 11th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Pieris Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $9.00.

Pieris Pharmaceuticals (NASDAQ PIRS) opened at $6.07 on Friday. Pieris Pharmaceuticals has a 52 week low of $1.34 and a 52 week high of $6.65.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 221.93% and a negative net margin of 321.83%. The firm had revenue of $3.93 million for the quarter, compared to the consensus estimate of $1.52 million. The business’s revenue for the quarter was up 400.3% compared to the same quarter last year. analysts expect that Pieris Pharmaceuticals will post -0.72 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in PIRS. Voya Investment Management LLC bought a new stake in shares of Pieris Pharmaceuticals during the 2nd quarter worth about $100,000. Wells Fargo & Company MN bought a new stake in shares of Pieris Pharmaceuticals during the 3rd quarter worth about $105,000. State of Wisconsin Investment Board bought a new stake in shares of Pieris Pharmaceuticals during the 2nd quarter worth about $132,000. The Manufacturers Life Insurance Company boosted its stake in shares of Pieris Pharmaceuticals by 1,106.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 29,150 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new stake in shares of Pieris Pharmaceuticals during the 2nd quarter worth about $162,000. Institutional investors own 50.45% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/12/03/pieris-pharmaceuticals-pirs-stock-rating-lowered-by-valuengine.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

What are top analysts saying about Pieris Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pieris Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit